[Editor's note: This infographic also appears in the February issue of In Vivo, along with an article detailing the 2021 business development activity for the top five firms. (Also see "Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020" - In Vivo, 17 February, 2022.)]
Who Were Big Pharma's Top Deal-Makers In 2021?
INFOGRAPHIC: Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.
More from Deals
More from Business
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.